Andrew Payne - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Andrew Payne

Showing results (11-20 of 20) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 20 results.

Brain, Behavior, and Immunity|July 15, 2023

Interleukin-10 enhances activity of ventral tegmental area dopamine neurons resulting in increased dopamine releaseJoakim W Ronström, Stephanie B Williams, Andrew Payne, et al.

Journal of Autoimmunity|May 4, 2020

Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseasesSijia Chen, Ross Paveley, Lianne Kraal, et al.

Bioorganic & Medicinal Chemistry Letters|November 26, 2008

Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitorsJohn Porter, Andrew Payne, Ben de Candole, et al.

Bioorganic & Medicinal Chemistry Letters|February 17, 2009

Atropisomeric small molecule Bcl-2 ligands: determination of bioactive conformationJohn Porter, Andrew Payne, Ian Whitcombe, et al.

Brain Sciences|October 25, 2024

Metabolic Pathophysiology of Cortical Spreading Depression: A ReviewArren Hill, Alfred B Amendolara, Christina Small, et al.

The Journal of Pharmacology and Experimental Therapeutics|April 27, 2017

Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K<i>δ</i>Rodger A Allen, Daniel C Brookings, Mark J Powell, et al.

Rheumatology (Oxford, England)|September 19, 2020

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndromeMaria Juarez, Nieves Diaz, Geoffrey I Johnston, et al.

Annals of the Rheumatic Diseases|November 26, 2018

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndromeSaba Nayar, Joana Campos, Charlotte G Smith, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 29, 2020

Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension StudiesNieves Diaz, Maria Juarez, Caterina Cancrini, et al.

Journal of Medicinal Chemistry|June 29, 2018

Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in VivoJames Reuberson, Helen Horsley, Richard J Franklin, et al.

Pageof 2

Search research articles

Showing results (11-20 of 20) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 20 results.

Brain, Behavior, and Immunity|July 15, 2023

Interleukin-10 enhances activity of ventral tegmental area dopamine neurons resulting in increased dopamine releaseJoakim W Ronström, Stephanie B Williams, Andrew Payne, et al.

Journal of Autoimmunity|May 4, 2020

Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseasesSijia Chen, Ross Paveley, Lianne Kraal, et al.

Bioorganic & Medicinal Chemistry Letters|November 26, 2008

Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitorsJohn Porter, Andrew Payne, Ben de Candole, et al.

Bioorganic & Medicinal Chemistry Letters|February 17, 2009

Atropisomeric small molecule Bcl-2 ligands: determination of bioactive conformationJohn Porter, Andrew Payne, Ian Whitcombe, et al.

Brain Sciences|October 25, 2024

Metabolic Pathophysiology of Cortical Spreading Depression: A ReviewArren Hill, Alfred B Amendolara, Christina Small, et al.

The Journal of Pharmacology and Experimental Therapeutics|April 27, 2017

Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K<i>δ</i>Rodger A Allen, Daniel C Brookings, Mark J Powell, et al.

Rheumatology (Oxford, England)|September 19, 2020

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndromeMaria Juarez, Nieves Diaz, Geoffrey I Johnston, et al.

Annals of the Rheumatic Diseases|November 26, 2018

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndromeSaba Nayar, Joana Campos, Charlotte G Smith, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 29, 2020

Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension StudiesNieves Diaz, Maria Juarez, Caterina Cancrini, et al.

Journal of Medicinal Chemistry|June 29, 2018

Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in VivoJames Reuberson, Helen Horsley, Richard J Franklin, et al.

Pageof 2